Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) announced it has dosed the first participant in a phase 1 clinical trial of EDP-978 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE